<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606826</url>
  </required_header>
  <id_info>
    <org_study_id>SARP003</org_study_id>
    <secondary_id>1U10HL109086</secondary_id>
    <nct_id>NCT01606826</nct_id>
  </id_info>
  <brief_title>Severe Asthma Research Program</brief_title>
  <acronym>SARP</acronym>
  <official_title>Severe Asthma Research Program</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mission of the SARP is to improve the understanding of severe asthma through integrated&#xD;
      study of its clinical and biological features and to evaluate their changes over time. The&#xD;
      ultimate goal of these efforts is to promote better treatments for severe asthma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mission of the SARP is to improve the understanding of severe asthma to develop better&#xD;
      treatments. The SARP will gain a better understanding of asthma and its endotypes, in&#xD;
      children and adults, by defining the disease at the molecular and cellular levels in the&#xD;
      context of the temporal phenotypic expression of the disease. To this end, the SARP&#xD;
      investigators will utilize both mechanistic and evoked phenotype approaches to: 1)&#xD;
      characterize developmental molecular, cellular and physiologic phenotypes in children and&#xD;
      adults with mild to severe asthma, and 2) to further elucidate the evolving pathobiology and&#xD;
      pathogenesis of severe asthma and its sub-phenotypes and 3) compare these features over time.&#xD;
      This approach involves a shared longitudinal protocol conducted across all participating&#xD;
      centers which includes common information on all SARP participants. Additionally, the SARP&#xD;
      investigators have each identified mechanistic research questions to be included in the&#xD;
      shared longitudinal protocol. Together, these longitudinal and mechanistic approaches will&#xD;
      enable prediction of phenotype stability/fluctuation and pharmacologic responses and&#xD;
      identification of novel, disease-modifying targets for treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2012</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary function test results</measure>
    <time_frame>36 months after enrollment</time_frame>
    <description>Pulmonary function test results include forced expiratory volume in one second (FEV1) and forced vital capacity (FVC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of severe asthma exacerbations</measure>
    <time_frame>36 months after enrollment</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Asthmatics</arm_group_label>
    <description>Subjects with active asthma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Subjects without any known pulmonary disease.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood: CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA; Urine; EBC; Sputum: Supernatant, Cell&#xD;
      Pellet; Bronch: BAL, Bronchial Brushings, Bronchial Biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target study population will is 80% adults (age 18 and older) and 20% children age 6-17&#xD;
        years, 50% females, and 30% minorities.&#xD;
&#xD;
        Approximately 100 Healthy Control patients, matching the demographic characteristics of the&#xD;
        asthma patients, will also be recruited in order to generate reference data for&#xD;
        biospecimens collected from asthmatic patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Asthmatic Patients:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Physician diagnosis of asthma,&#xD;
&#xD;
          2. Age 6 years and older&#xD;
&#xD;
          3. Evidence of historical reversibility, including either:&#xD;
&#xD;
               -  FEV1 bronchodilator reversibility ≥ 12%, or&#xD;
&#xD;
               -  Airway hyperresponsiveness reflected by a methacholine PC20 ≤16 mg/mL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy during the characterization phase,&#xD;
&#xD;
          2. Current smoking,&#xD;
&#xD;
          3. Smoking history &gt; 10 pack years if ≥30 years of age, or smoking history &gt; 5 pack years&#xD;
             if &lt;30 years of age (Note: if a subject has a smoking history, no smoking within the&#xD;
             past year),&#xD;
&#xD;
          4. Other chronic pulmonary disorders associated with asthma-like symptoms, including (but&#xD;
             not limited to) cystic fibrosis, chronic obstructive pulmonary disease, chronic&#xD;
             bronchitis, vocal cord dysfunction (that is the sole cause of respiratory symptoms and&#xD;
             at the PI's discretion), severe scoliosis or chest wall deformities that affect lung&#xD;
             function, or congenital disorders of the lungs or airways,&#xD;
&#xD;
          5. History of premature birth before 35 weeks gestation,&#xD;
&#xD;
          6. Unwillingness to receive an intramuscular triamcinolone acetonide injection,&#xD;
&#xD;
          7. Evidence that the participant or family may be unreliable or poorly adherent to their&#xD;
             asthma treatment or study procedures,&#xD;
&#xD;
          8. Planning to relocate from the clinical center area before study completion,&#xD;
&#xD;
          9. Any other criteria that place the subject at unnecessary risk according to the&#xD;
             judgment of the Principal Investigator and/or attending physician(s) of record, or&#xD;
&#xD;
         10. Currently participating in an investigational drug trial for asthma therapies.&#xD;
&#xD;
        Healthy Controls:&#xD;
&#xD;
        Inclusion criteria: Healthy subjects between the age of 18 and 65 years. Exclusion criteria&#xD;
&#xD;
          1. History of chronic diseases that affect the lungs,&#xD;
&#xD;
          2. A history suggestive of allergic rhinitis, eczema or chronic sinusitis,&#xD;
&#xD;
          3. An improvement in FEV1 of more than 12% following 4 puffs of albuterol,&#xD;
&#xD;
          4. Smoking history &gt; 10 pack years if ≥30 years of age, or smoking history &gt; 5 pack years&#xD;
             if &lt;30 years of age, or any smoking within the past year,&#xD;
&#xD;
          5. Respiratory tract infection within the past 4 weeks,&#xD;
&#xD;
          6. Pregnancy,&#xD;
&#xD;
          7. History of premature birth (&lt;35 weeks).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally Wenzel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elliot Israel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham &amp; Women's Hospital, Boston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Levy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham &amp; Women's Hospital, Boston</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Fahy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suzy Comhair, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Loren Denlinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wendy Moore, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Castro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Mauger, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Mauger, PhD</last_name>
    <phone>717-531-7178</phone>
    <email>dmauger@psu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kendall Baab</last_name>
    <phone>717-531-7178</phone>
    <email>kthomas@phs.psu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Wong McGrath</last_name>
      <phone>415-476-5043</phone>
      <email>Kelly.Wong@nursing.ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>John Fahy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Dioneda</last_name>
      <phone>617-732-6641</phone>
      <email>bfopmrfs@partners.org</email>
    </contact>
    <investigator>
      <last_name>Elliot Israel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruce Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparito Cunningham</last_name>
      <phone>857-218-5531</phone>
      <email>Amparito.cunningham@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Wanda Phipatanakul, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Weaver</last_name>
      <phone>314-362-3627</phone>
      <email>rweaver@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Mario Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Smith</last_name>
      <phone>336-713-8551</phone>
      <email>rvsmith@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Eugene Bleecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rainbow Babies and Children's Hospital, Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Logan</last_name>
      <phone>216-844-7927</phone>
      <email>Laurie.Logan@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>James Chmiel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin Gaston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmea Mattox</last_name>
      <phone>216-636-5149</phone>
      <email>cleggee@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Serpil Erzurum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Martin, BSN CCRC</last_name>
      <phone>412-692-4747</phone>
      <email>martinlp@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Sally Wenzel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908-0386</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Wavell</last_name>
      <phone>434-924-6874</phone>
      <email>kww7d@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Gerald Teague, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Crisafi</last_name>
      <phone>608-263-0524</phone>
      <email>pulm-research@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Nizar Jarjour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.severeasthma.org/</url>
    <description>Severe Asthma Research Program (SARP) Public Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>May 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2012</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>dave mauger</investigator_full_name>
    <investigator_title>Professor of Public Health Sciences</investigator_title>
  </responsible_party>
  <keyword>Severe</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

